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Background: One of the many challenges which come together with the implementation of antiretroviral
therapy (ART) in settings with limited resources is the monitoring of toxicity. This monitoring increases
costs of ART and strains resources. We therefore investigated the necessity for laboratory toxicity
monitoring of ART in Thailand.
Design, methods and participants: A prospective Thai cohort of 417 HIV-infected patients were enrolled
in randomized clinical trials investigating ART. Time-dependent occurrence of grade III/IV abnormal
laboratory values as defined by the AIDS Clinical Trial Group was analysed.
Results: During a median observation period of 3.7 years (2.4–4.3) 142 grade III/IV toxicities occurred in
101 (24.2%) patients. Hepatic toxicity (n = 33, 7.9%), hypercholesterolaemia (n = 57, 13.7%),
hypertriglyceridaemia (n = 26, 6.2%), anaemia (n = 16, 3.8%) and low platelet counts (n = 8, 1.9%) were
frequently observed. Anaemia and low platelets occurred early and during the first 2 years of ART.
Hepatic toxicity was seen early and throughout the observation period. Hypertriglyceridaemia and
hypercholesterolaemia occurred throughout the observation period, and increased over time.
Hypercreatininaemia and hyperglycaemia occurred once after 120 and 132 weeks. ART was changed
or interrupted for grade III/IV hepatic toxicity, anaemia and hyperglycaemia only. The incidence rate
for grade III/IV toxicity was between 5.56 (95% CI, 6.76–18.02) for low platelet counts and 41.18 (31.77–
53.39) per 1000 patient years for hypercholesterolaemia. Antiretrovirals used were zidovudine,
stavudine, lamivudine, zalcitabine, didanosine, efavirenz, saquinavir, ritonavir and indinavir.
Conclusions: Grade III/IV toxicity is frequently observed in Thai patients treated with ART. The simple
and inexpensive monitoring of ALT and haemoglobin could prevent most serious short-term toxicity.
Long-term toxicity can be addressed with a yearly monitoring of triglycerides, cholesterol, glucose and
creatinine if nephrotoxic drugs are used.
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Introduction
Antiretroviral therapy (ART) has proven to be highly effective in
the treatment of HIV infection in industrialized countries1,2 as
well as in countries with limited resources.3–10 But ART also has
significant toxicity that requires monitoring.11–27 Laboratory tests
performed on a regular basis are usually used to detect severe
toxicity before it becomes clinically apparent and harmful. These
tests however are costly and require patient visits, phlebotomy,
and appropriate infrastructure and equipment. So far, due to
.............................................................................................................................................................................................................................................................................................................................................................................................................................
*Correspondence address. Outpatient Department of Internal Medicine, University Hospital Basel, CH-4031 Basel, Switzerland.
Tel: +41-61-2652525; Fax: +41-61-2654604; E-mail: nueschr@uhbs.ch
†Members are listed in the Acknowledgements section.
.............................................................................................................................................................................................................................................................................................................................................................................................................................
637
 The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oxfordjournals.org
JAC
antiviral
financial constraints and the lack of appropriate infrastructure,
ART is mostly used in developed countries where such
infrastructure is available. However, considerable efforts are
being undertaken worldwide to expand the access to ART in
resource limited settings.5,28–30 One of the many challenges which
comes together with the implementation of ART in such areas is
the monitoring of toxicity.31,32 Knowing when toxicity is most
likely to occur, and what parameters call for a change in therapy,
would help to avoid unnecessary examinations and costs. The
interval at which safety monitoring is performed varies consider-
ably depending on local practice, availability of tests and
resources. Despite the fact that safety laboratory examinations
are considered to be the standard of care, evidence on when to
perform which test is scarce. Most data are available from clinical
trials with an emphasis on maximal safety. Also, some
randomized clinical trials evaluating the efficacy of antiretrovirals
(ARV) were not powered to detect side effects. Especially in
resource limited settings like in Thailand, safety laboratory
monitoring significantly adds to the costs of ART.33,34 With
cheaper ARV becoming available, an increasing number of HIV-
infected patients will be treated and will have to be monitored for
side effects.5–7 To provide evidence on how safety monitoring
could be most efficiently performed we conducted an analysis in
patients treated within different trials and with different
antiretroviral drugs in Thailand.
Methods
Study design
The study population included HIV-infected adults participating in
randomized controlled trials of ART at HIV-NAT, Bangkok,
Thailand, who initiated therapy between December 1996 and
December 2002. Patients were recruited from the HIV outpatient
clinic of the Chulalongkorn Hospital and the anonymous clinic of the
Thai Red Cross in Bangkok, Thailand. All protocols were approved
by the institutional review board of the Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand. All patients gave
written informed consent. In accordance with trial protocols, clinical
and laboratory data were collected at screening (within 4 weeks
before ART commencement), baseline (just prior to ART commence-
ment) and every 6 weeks to 12 weeks depending on the trial protocols
up to week 378. Pathological grade III/IV results were graded
according to the AIDS Clinical Trial Group (ACTG) toxicity grading
system (http://aactg.s-3.com): haemoglobin < 7.4 g/dL, platelets
< 50 000 platelets/mm3, ALT > 5· upper limit, creatinine > 1.9·
upper limit, triglycerides > 8.49 mmol/L, cholesterol > 7.77 mmol/L,
glucose <2.2 and >13.9 mmol/L. Other tests used in the studies but
excluded from the analysis were amylase, neutrophils, lymphocytes,
monocytes, eosinophils, basophils, CD8, lactate. Reasons for
exclusion were that measurements were available only for a few
patients (amylase, lactate) and that no grade III/IV toxicity occurred
(all of these tests).
Data analysis and statistics
In order to detect patterns in the occurrence of toxicity, the database
was screened for haemoglobin, leucocyte count, platelet count, ALT,
serum creatinine, cholesterol, triglycerides and glucose. Relevant
events defined as grade III or IV toxicity were analysed separately.
Univariate and multivariate Cox regression analyses were used to
detect factors associated with severe (grade III and IV) toxicity.
Variables that were statistically significant in the univariate models
then would be selected to be in the multivariate models to see whether
they still had the same effects. Incidence rates for each endpoint per
1000 patients per year were also calculated. Nelson-Aalen function
was used to calculate failure rates in each endpoint. For statistical
analysis STATA version 8.2 (StataCorp, USA) was used. Level of
significance in this paper is 0.05 and all P values in the study are
two-sided.
Results
A total of 417 patients participating in HIV-NAT 001 (n = 111),
002 (n = 78), 003 (n = 106), 005 (n = 104) and 009 (n = 18)35–43
trials between December 1996 and December 2002 were
analysed. Drug regimens used in the different trials were
zidovudine/zalcitabine standard versus half dose,37 dual nucleo-
side plus boosted saquinavir,35,36,40,42 didanosine/stavudine
versus zidovudine/lamivudine,38 zidovudine/lamivudine/
didanosine,39,43 zidovudine/lamivudine/boosted indinavir44 and
boosted indinavir/efavirenz.41 Exclusion criteria in the protocols
were (i) protease inhibitor-experienced; (ii) liver function tests
>5 times upper normal limit, creatinine >2 times upper normal
limit.
Median (IQR) observation period was 3.7 years (2.4–4.3)
accounting for 1677 patient years. Mean (SD) time on HAART
was 2.09 (1.6) years. Baseline characteristics of the patients
are shown in Table 1. As expected in a cohort with predo-
minately heterosexual transmission (89.0%), female to male ratio
Table 1. Baseline characteristics of patients at inclusion into
trials, and overall exposure to antiretrovirals
Characteristic
Number of patients 417
Age [years (SD)] 32.2 (7.2)
Female/male [n (%)] 224/193 (53.7/46.3)
Transmission category [n (%)]
heterosexual 371 (89.0)
homosexual 30 (7.2)
injecting drug users 3 (0.7)
heterosexual/bisexual 10 (2.4)
other 3 (0.7)
CDC clinical stage [n (%)]
A 224 (53.8)
B 159 (38.0)
C 34 (8.2)
Viral load [log10 copies/mL (IQR)] 4.3 (3.7–4.9)
CD4 cells [cells/mm3 (IQR)] 283 (179–392)
ARV naive/experienced 295/122 (70.7/29.3)
Drugs ever used [n (%)]
zidovudine 372 (89.2)
lamivudine 307 (73.6)
didanosine 217 (52.0)
stavudine 189 (45.3)
zalcitabine 111 (26.6)
efavirenz 62 (14.9)
indinavir 165 (39.6)
saquinavir 95 (22.8)
ritonavir boosting dose 192 (46.0)
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was balanced (1.16). A total of 142 grade III/IV toxicity events
occurred in 101 patients within a maximum observation period of
378 weeks. When severe toxicity occurred, patients most
frequently experienced hypercholesterolaemia (n = 57, 13.7%),
elevation of ALT (n = 33, 7.9%), triglycerides (n = 26, 6.2%) and
a decline in haemoglobin (n = 16, 3.8%) followed by low platelet
counts (n = 8, 1.9%). No hypoglycaemia occurred. Hyperglycae-
mia and high creatinine in a patient taking indinavir were
observed only once. The time-dependent occurrence of grade III/
IV toxicity on ART is shown in Figure 1. Whereas anaemia is
observed predominately during the first 2 years of ART, elevation
of liver enzymes, triglycerides and cholesterol occurred
throughout the observation period. The first grade III/IV anaemia
(n = 3) and ALT elevation (n = 5) occurred at week 12, the first
low platelet count (n = 1) at week 6. First grade III/IV
hyperlipidaemia was observed after 12 weeks on ART. Only
one isolated incidence of elevated creatinine and one hypergly-
caemia occurred after 120 and 132 weeks, respectively. ART was
interrupted in 15 of the 16 (93.8%) patients who experienced
severe anaemia and changed in 2 (12.5%) without discontinuation
(Table 2). Hepatic toxicity was observed in 33 patients and
triggered interruption of ART in 14 (42.4%). One patient
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Figure 1. Occurrence of grade III/IV toxicity over time shown with Nelson Aalen’s plots.
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experienced hyperglycaemia and his therapy was interrupted. No
therapy was interrupted because of low platelet counts and grade
III/IV hyperlipidaemia. Also, no change in the ARV was triggered
by abnormal creatinine (Table 2). Incidence rates per 1000 patient
years (with 95% confidence interval) of severe toxicity were 5.56
(2.78–11.13) for low platelet counts, 41.18 (31.77–53.39) for
hypercholesterolaemia, 11.04 (6.76–18.02) for severe anaemia,
18.42 (12.54–27.05) for hypertriglyceridaemia and 23.86 (16.96–
33.56) for elevated liver enzymes. We used Cox proportional
hazards models to determine factors related to grade III/IV
toxicity (Table 3). In the univariate analysis anaemia was
associated with the use of zidovudine. Older age was significantly
associated with liver toxicity. Hyperlipidaemia was associated
with older age, advanced HIV disease, and treatment with
efavirenz and indinavir, whereas patients naive to ART, patients
with higher CD4 count, and patients using zidovudine and
didanosine had lower lipid values. In the multivariate analysis
older age, the use of indinavir, the inverse correlation with higher
CD4 count, didanosine and ARV naive status remained
significantly associated with hyperlipidaemia.
Discussion
Significant toxicity of ART was frequently observed in this
Thai cohort of patients treated within various clinical trials.
Grade III/IV toxicity of ART occurred with an incidence rate
5.56–41.18 per 1000 patient years. A total of 142 grade III/IV
laboratory adverse events were recorded in 101 (24.2%) patients.
Due to toxicity, therapy had to be changed or interrupted in 30 of
the 417 (7.2%) patients analysed. No mortality was attributed to
drug toxicity.
In accordance with population-based studies in industrialized
countries 12,14,16,23,27,45 our data show that toxicity is a significant
problem in Thai patients treated with ART. The incidence of
grade III/IV laboratory adverse events was higher than that in
industrialized countries,12,27,45 but similar to investigations in
other resource limited settings.10,46 One reason for this could be
the lack of therapeutic alternatives. Many patients had to continue
their treatment despite low-grade toxicity. Switching ARV for
any-grade toxicity is indeed the most frequent reason to change
ARV in industrialized countries.17,23,47 Switches for low-grade
toxicity may have prevented grade III/IV toxicity. Accordingly
switches due to grade III/IV laboratory toxicity occurred in 6.7%
of Thai patients. This is about twice as frequent as in
industrialized countries.47 Hepatic toxicity was frequently
observed. This may be due to fact that chronic hepatitis B or C
co-infection is common in HIV-infected Thai patents.48 In our
study 8% suffered from chronic viral hepatitis. It has been shown
that such co-infection puts patients at a higher risk for developing
grade III/IV liver enzyme elevations.21,48 Grade III/IV elevation
in ALT was judged by the treating clinicians to be serious, and
ART was frequently interrupted due to ALT elevation. The other
abnormalities that caused changes in therapy were severe anaemia
and hyperglycaemia. Low platelet counts resolved while on ART
and were probably not drug related. Thus, monitoring of only
ALT and haemoglobin would have been enough to detect nearly
all of the significant short-term toxicity.
No change in therapy was triggered by hyperlipidaemia.
However, newer data shows an increased cardiovascular risk for
patients treated with ART.16 So far cardiovascular mortality is not
an extensive problem for HIV-infected persons in developing
countries. The high mortality of untreated HIV infection com-
bined with younger age and a high proportion of female patients
make a cardiovascular event unlikely. This may change if ART
becomes more widely accessible, and life expectancy of HIV-
infected patients increases also in the economically less devel-
oped countries. Due to the lack of funding to perform testing there
is no data on cardiovascular toxicity of HAART in Thai patients.
However, this needs to be followed carefully as HAART becomes
more widely available in this country. We did show that
hyperlipidaemia develops steadily over time, suggesting that
continuous monitoring at a low frequency, i.e. every 1–2 years, is
sufficient to detect this long-term cardiovascular risk factor.
Nevertheless, ART has shown to be beneficial even without
laboratory monitoring for side effects.4 Indeed the rate of life-
threatening toxicity in our cohort is still well below the rate of
progression to AIDS without ART. A cohort of patients in an
industrialized country showed a progression to AIDS of 15.1 per
100 patient years 6 months prior to ART.49 The same analysis also
showed a striking reduction in the progression to AIDS 3 and 6
months after starting ART form 15.1 to 7.7 and 2.2 per 100 patient
years, respectively.49 Other cohorts in industrialized countries
have reported progression rates to new AIDS-defining events of
2.6–4.8 per 100 patient years.2,50,51 In our cohort progression to
new AIDS-defining events and mortality were 1.7 and 0.7 per 100
patient years.8 Tuberculosis, which is endemic in Thailand, was
the most frequent new AIDS-defining disease (14 of 29 events).
The impact of ART in these Thai patients is thus at least as
significant as in industrialized countries. But severe toxicity was
frequently observed and would probably have caused some
Table 2. Occurrence, management and devolution of grade III/IV toxicity events per patient who experienced toxicity
Toxicity No. of patients ART changeda ART interrupteda Resolutionb Persistence/recurrence
ALT >5· upper limit 33 8 14 20 13
Haemoglobin < 7.4 g/L 16 2 15 15 1
Platelets < 50 000 platelets/mm3 8 0 0 8 0
Cholesterol > 7.77 mmol/L 57 0 0 15 42
Triglycerides > 8.49 mmol/L 26 0 0 12 14
Hyperglycaemia > 13.9 mmol/L 1 0 1 0 1
Creatinine >1.9· upper limit 1 – – – –
aMultiple mentioning.
bToxicity of grade II or less during follow up.
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additional morbidity and mortality without proper management.
In this context it is interesting how toxic events occurred over
time (see Figure 1). Haematological toxicity happened early and
was observed during the first 2 years of follow up. To detect such
toxicity, safety monitoring has to start early, 12 weeks at the
latest, and continue for the first 2 years of treatment. Whereas
hepatic toxicity can occur early and may continue to arise even
after 150 weeks. Therefore, monitoring starting after 12 weeks on
treatment and continuing during the whole treatment period is
required to detect it. Hypertriglyceridaemia occurred without
distinct patterns throughout the observation period and became
more frequent in the later course of ART. This is particularly true
for hypercholesterolaemia, which predominately occurred after
more than 200 weeks on therapy. This was because patients
became older during the observation period and the use of boosted
protease inhibitors was more frequent. Both factors were
associated with hyperlipidaemia in the multivariate analysis.
Grade III/IV renal toxicity and hyperglycaemia were very rare and
happened only after more than 2 years on treatment. But grade I/II
nephrotoxicity was frequently observed in patients taking
indinavir in HIV-NAT studies.44 So checking creatinine on a
yearly basis should be considered.
In order to determine patients at particular risk for toxicity, we
analysed various factors that are shown in Table 3. Grade III/IV
hepatotoxicity was weakly associated with older age. As
expected, hyperlipidaemia was associated with the use of protease
inhibitors like indinavir. Older patients developed hyper-
cholesterolaemia more frequently, while the use of didanosine
at baseline was associated with lower cholesterol. Overall we
could not find any predictive risk factors for the development of
toxicity, suggesting that all patients taking ART should be
monitored for side effects.
Some limitations in our study should be considered. The
number of ARVs used is restricted. Therefore the conclusions can
only be generalized with some caution to any combination of
antiretroviral drugs. On the other hand many drugs have
overlapping toxicity. And newer drugs tend to have even fewer
side effects than the one used. For example, tenofovir may require
toxicity monitoring including more frequent measurements of
creatinine and excluding monitoring for toxicity the drug does
not have. Therefore the main conclusion that toxicity can be
addressed with just a very few tests is not affected by the limited
choice of drugs. Another limitation is the sample size. Some
factors related to grade III/IV toxicity may not have been detec-
ted because of too small numbers. And the selected nature of
participants within clinical trials may have led to an under-
estimation of toxicity. On the other hand, the long follow up
strengthens the conclusions. And the standardized setting
within randomized trials has reduced cofounders and selection
bias.
Grade III/IV toxicity is frequently observed in Thai patients
treated with ART. Although the decrease in the incidence of
progression of HIV infection induced by ART largely outweighs
toxic effects, life-threatening toxicity occurs. Focusing toxicity
monitoring on the few parameters which trigger a change in
therapy such as ALT and haemoglobin could prevent most of the
severe short-term toxicity of ART and further increase its
beneficial effects in countries with limited resources. Where
possible, long-term toxicity should be addressed with a yearly
monitoring of triglycerides, cholesterol, glucose and creatinine if
nephrotoxic drugs are used.
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